Skip to main content
. 2018 Aug 8;4(8):eaas9846. doi: 10.1126/sciadv.aas9846

Fig. 5. Treatment with probenecid, a broad-spectrum Panx1 blocker, alleviates MIA-induced pain behaviors.

Fig. 5

(A) Mechanical paw withdrawal threshold assessed by von Frey filaments using the SUDO method in rats injected twice daily intraperitoneally with probenecid (PRB) or saline [CTR/SA, n = 6; MIA/SA, n = 6; MIA/PRB (100 mg/kg), n = 6]. Baseline threshold in gram force: 14.5 g. (B) IL-1β levels in rat CSF 7 days after intra-articular MIA/CTR and daily intraperitoneal injection of saline or probenecid (CTR/SA, n = 6; MIA/SA, n = 6; MIA/PRB 100 mg/kg, n = 6). (C) Mechanical paw withdrawal threshold assessed by von Frey filament test on day 7 after MIA-induced joint injury (saline, n = 6; probenecid 50 mg/kg, n = 6; probenecid 100 mg/kg, n = 4). (D) IL-1β levels in rat CSF 7 days after intra-articular MIA/CTR and acute intraperitoneal injection of saline or probenecid (CTR/SA, n = 4; MIA/SA, n = 8; MIA/PRB 100 mg/kg, n = 8). (E and F) Dynamic weight bearing assessed on day 7 after MIA-induced joint injury (CTR/PRB, n = 8; MIA/PRB, n = 7; MIA/SA, n = 8). Effect of probenecid (50 mg/kg) on (E) weight bearing (day 7; P = 0.0036, two-way ANOVA) and (F) paw surface area (day 7; P = 0.05, two-way ANOVA). Arrow represents single intraperitoneal injection of probenecid. *P < 0.05; **P < 0.01, two-way repeated-measures ANOVA (A, C, E, and F) and one-way ANOVA (B and D) followed by Sidak or Bonferroni post hoc tests.